SCIENTIFIC REPORT ISTITUTO ONCOLOGICO VENETO I.R.C.C.S.

Size: px
Start display at page:

Download "SCIENTIFIC REPORT 2010-2011 ISTITUTO ONCOLOGICO VENETO I.R.C.C.S."

Transcription

1 SCIENTIFIC REPORT ISTITUTO ONCOLOGICO VENETO I.R.C.C.S.

2

3 CONTENTS FOREWORD 5 THE INSTITUTE 9 Chief Officer Address 13 The IOV Governance 16 CLINICAL ACTIVITY ORGANIZATION 19 Chief Medical Officer Report 21 Clinical Activity Data 24 Multidisciplinary Groups 28 THE DEPARTMENTS 31 Department of Clinical Oncology 33 Clinical Oncology 1 34 Clinical Oncology 2 46 Evaluation and Introduction of New Drugs in Cancer Therapy 54 Department of Surgery 57 Surgical Oncology 58 Breast Surgery 64 Melanoma and Soft Tissue Tumors 68 Diagnostic and Operative Endoscopy 76 Anesthesiology 82 Department of Imaging, Radiology and Pathology 89 Radiology 90 Breast Imaging 96 Pathology 104 Department of Radiotherapy and Nuclear Medicine 107 Radiotherapy and Nuclear Medicine 108 Medical Physics 120 Department of Experimental, Laboratory and Translational Oncology 127 Immunology and Molecular Oncology 128 Hereditary Endrocrine Cancer Unit 154 Department of Services 161 Pharmacy 162 Cardiology 168 Psycho-Oncology 172 Tumor Registry 178 THE RESEARCH 185 Scientific Director Address 187 General Considerations 188 Scientific Directorate Organization 191 SWOT Analysis 195 Research: Input and Output 197 Clinical Trials and Biostatistics Unit 202 Strategic Scientific Options 209 Pharmacogenomics 212 Cancer Stem Cells 214 RESEARCH ACTIVITY REPORT 217 Line 1 - Tumor Epidemiology and Prevention 218 Introduction 218 Workflow Project List 219 Line 2 - Mechanisms of Cancerogenesis 220 Introduction 220 Workflow Project List 221 Line 3 - Instrumental and Molecular Approaches for Diagnosis, Staging and Follow-Up 222 Introduction 222 Workflow Project List 223 Line 4 - Innovative Therapeutic Approaches: Chemotherapy, Radiotherapy and Surgery 226 Introduction 226 Workflow Project List 227 CONTENTS 3

4 Line 5 - Tumor Immunology and Innovative Therapeutic Approaches 230 Introduction 230 Workflow Project List 231 Line 6 - Quality of Life in Cancer Patients and Geriatric Oncology 232 Introduction 232 Workflow Project List 233 CLINICAL RESEARCH 235 Ethics Committee 236 Clinical Trials 237 VENETO ONCOLOGY NETWORK 245 EDUCATION 249 Internal Education & Training 250 Post-graduate Schools 255 Meetings and Seminars 257 AWARDS 261 PUBLICATIONS 265 INDEx 305 CONTENTS 4

5 FOREWORD FOREWORD 5

6 This volume is the third edition of the Scientific Report of the IRCCS-Istituto Oncologico Veneto (IOV), and its format is very similar to that of the Report; since research programs which characterize the scientific profile of the Institute mostly have a wide breath, we felt that a biennial report of the results achieved and the developments foreseen could be appropriate. Again, we chose to publish this Report in English to stress the international dimension in which the Italian IRCCS must confront, and to underline the meaning of the report itself, as we intend it. Indeed, data reported in this kind of publications are also available in the yearly reports forwarded to the Italian Health Ministry; in any case, the array of research projects focused on specific aspects of oncologic research (the socalled Ricerca Corrente Programs) is summarized in a dedicated Section. We instead decided to privilege the presentation to colleagues involved in our field in Italy and abroad a more faithful and comprehensive profile of the Institution we are working in. For this purpose, we gave more room to the analytical description of the Departments and of the clinical and research activities of the individual Units, who were asked to present in a more extended way a selection of their leading programs. The presence at the end of the book of an Analytical Index witnesses our hope to render this book a useful tool for researchers in Italy and abroad to establish new fruitful interactions on specific topics of interest. We did not feel it appropriate to distinguish our research activities into basic, translational and clinical investigation. Firstly, we are firmly convinced that only two types of research exist, good research and bad research. Secondly, progress is only achieved by the steady crosstalk of scientists belonging to very distant areas, and the interconnection of different FOREWORD 6

7 disciplines is terrific; it is impossible to foresee the future fallouts of an apparently basic research on the clinical management of patients in terms of diagnosis or therapy. In the light of the modern concepts in Oncology and more in general in Medicine, our work must go from bed to bench and back from bench to the bed, in search of innovative markers of disease and therapeutic targets. In this perspective, all the work at the Institute is carried out in a multidisciplinary way; this means that for every oncologic disease a group of concerned and dedicated workers (medical oncologists, radiologists, radiotherapists, surgeons, psychologists etcetera) strictly interact in the daily effort to provide patients with the best state-of-the-art standards of care. On the other hand, we are perfectly aware that clinicians and researchers also are only a part of the story. What we are daily carrying out in our labs, guards, and operating theaters would be vane, if our activities were not complemented by the steady help of many people more or less directly involved in the management of the oncological disease. These include a wealth of persons, from the patients themselves to their relatives and caregivers, the nurses, the many volunteers belonging to the different Associations, and many others. This plethora of humble, often unknown, generous people do not have a place in this book, but without them our research would be a sterile, solipsistic exercise. To this silent multitude our grateful thinking; the struggle against cancer is a multifaceted task, and if we want to transform cancer into a curable disease, the efforts of everybody will be essential. Alberto Amadori, Scientific Director FOREWORD 7

8

9 THE INSTITUTE THE INSTITUTE 9

10 The Institute The IRCCS Istituto Oncologico Veneto (Veneto Oncology Institute - IOV) was established in December 2005, after obtaining recognition of its scientific character from the Italian Health Ministry; following a site visit in 2008, this qualification was confirmed by the Ministry. The Institute has a juridical personality, and it is subordinate to both Veneto Regional Authorities and the Ministry of Health. The IOV is the only Cancer Center in the Veneto region; it participates in the Italian network of Cancer Institutes (Alliance Against Cancer), which includes the Italian Cancer Centers under the patronage of the Istituto Superiore di Sanità in Rome. Since January 2009, the IOV is a member of the Organization of European Cancer Centers (OECI), that includes over 70 Comprehensive Cancer Centers in Europe. The IOV stems from a long tradition of excellence in Oncology, which was first recognized in 1989 by the establishment of the Regional Oncology Center (COR) in Padova. The activity of COR was mainly devoted to fostering interactions among epidemiologists, clinicians and basic researchers in the field of Oncology, and to create a multidisciplinary approach to face the new frontiers of information on cancer genetics and biology. This strict collaboration among professionals involved in different areas of Oncology anticipated the modern concept of translational medicine, now considered as a strategic field within evidence-based medicine. Moreover, the IOV is a true Comprehensive Cancer Center, since it integrates in its mission clinical activity, research and education: the IOV offers, in fact, preventive, curative and palliative services to the population, and it combines this fundamental mission with a constant research activity on several different aspects of cancer, as well as maintaining a special commitment to educational issues, in strict collaboration with the Faculty of Medicine of the Padova University. The IOV is located in Padova in close proximity to the University Hospital, within an area known as Ospedale Busonera, a hospital that was established in 1932 and was formerly dedicated to the care of tuberculosis patients. For this reason, the Ospedale Busonera is embedded in a park of about 40,000 square meters, populated by a collection of rare and magnificent trees, whose balsamic properties were thought to aid the recovery of tuberculosis patients; according to a recent agreement with the mayor of Padova, this park will soon be fully restored, and its beautiful environs shared by our patients and the general public. Because of its peculiar architectural characteristics, the major body of the hospital (recently flanked by a modern laboratory building) is under the patronage of the Artistic Superintendence of the Veneto Region; despite the great attention to our needs and the generous collaboration provided by this Authority, any refurbishment of the structures is complex and difficult. THE INSTITUTE 10

11 Aerial view of the Busonera area THE INSTITUTE 11

12 Map of Busonera Hospital area in the 30 s THE INSTITUTE 12

13 Chief Officer Address THE INSTITUTE - CHIEF OFFICER ADDRESS 13

14 Chief Officer Address When we started the project of the IOV, just five years ago, even with the most steady optimism we could not have thought that we would set up what has been created. The Veneto Region had believed in this project and the Italian Ministry of Health too, but we had an aura of skepticism and doubts around, that did not leave us completely calm. Today we can say we have worked hard and we have all worked well. Results are more than satisfying both in terms of clinical care and of research and innovation. IOV is recognized as a reality at a regional, national and international level. In this report, which sheds light on the improvements of the last two years and on the work in progress, the achievements and the goal under implementation are described in detail. I would like to underline two important targets: the first is the extraordinary solidarity and generosity of our citizens already from the first year, the second is that the economic balance of the Institute has always been positive before tax, and today we have a significant income proving that also a public institution, even in its start-up, can be not a burden for the taxpayer, but an investment both at a scientific and a working level, as demonstrated by the patents taken out and now under development. We were few dozen of people at the beginning, today we are more than five hundred persons dedicated to research and medical care in the interests of the welfare of our patients. Thanks to each of you. Pier Carlo Muzzio THE INSTITUTE - CHIEF OFFICER ADDRESS 14

15

16 The IOV Governance The IOV is governed through the joint and coordinated effort of a Directive Board, which includes several persons each endowed with specific commitments and interacting within the Strategic Directorate. General Directorate: legal representative of the Institution, responsible for legal and administrative affairs, through an Administrative Directorate. Scientific Directorate: responsible for scientific research and all activities connected to the scientific life of the Institute. The organization, monitoring and evaluation of clinical activities is the responsability of the Medical Directorate. According to the Italian law and regulations, the Institute functioning is superintended by a specific Committee (Comitato di Indirizzo e Verifica, CIV), whose duty is to supervise the strategic decisions of the General Directorate, to verify all the administrative aspects of the Institute, and to suggest lines of development to the Scientific Directorate, in order to guarantee a harmonic and fruitful development of the life and mission of the Institute. The CIV includes members endowed with scientific and administrative expertise, and it is presently composed by the following persons: Prof. Ermanno Ancona (President), Prof. Carlo Foresta, Dr. Eligio Grigoletto, Dr. Claudio Paccanaro and Dr. Adriano Paccagnella. The following diagram schematically illustrates the basic organization of the Institute. THE INSTITUTE - CHIEF OFFICER ADDRESS 16

17 GENERAL DIRECTORATE SCIENTIFIC DIRECTORATE ADMINISTRATIVE MARKETING & DIRECTORATE COMMUNICATION ECONOMICAL AFFAIRS IMAGING, RADIOLOGY & PATHOLOGY LEGAL AFFAIRS RADIOTHERAPY & NUCLEAR MEDICINE MEDICAL DIRECTORATE CLINICAL ONCOLOGY EDUCATION SURGERY LIBRARY RESEARCH LABORATORIES SERVICES RESEARCH ADMINISTRATION CLINICAL TRIALS & BIOSTATISTICS UNIT EXPERIMENTAL LABORATORY & TRASLATIONAL ONCOLOGY A S F A R A S S C I E N T I F I C A C T I V I T I E S A R E C O N C E R N E D BREAST IMAGING PATHOLOGY CLINICAL ONCOLOGY 1 CLINICAL ONCOLOGY 2 CARDIOLOGY PSYCHO- ONCOLOGY RADIOLOGY EVALUATION & INTRODUCTION OF NEW DRUGS IN CANCER THERAPY PHARMACY TUMOR REGISTRY MEDICAL PHYSICS RADIOTHERAPY & NUCLEAR MEDICINE SURGICAL ONCOLOGY BREAST SURGERY MELANOMA & SOFT TISSUE TUMORS IMMUNOLOGY & MOLECULAR ONCOLOGY HEREDITARY ENDOCRINE CANCER UNIT DIAGNOSTIC & OPERATIVE ENDOSCOPY ANESTHESIOLOGY THE INSTITUTE - CHIEF OFFICER ADDRESS 17

18 GENERAL DIRECTORATE Pier Carlo Muzzio (Director) Francesca Pagnin Bruno Bandoli (Marketing, Communication and Fund Raising) Flavia Dalla Rosa Daniela Chiusole (Certification and Quality Assurance) Marco Tria Maurizio Peci Andrea Azzalini Isabella Colpo Salvatore D Amico Giuseppe Borella Ampelio Preo Marcello Valente SCIENTIFIC DIRECTORATE Alberto Amadori (Director) Daniela Battistuzzi Manuela Mtanis Mauro Apostolico Alessandro Andretto Gian Luca De Salvo Denise Marie Kilmartin Paola Del Bianco MEDICAL DIRECTORATE Maria Giacobbo (Director) Maria Pia Bellavere Antonella Frasson Maria Padovan (Nurses and Research Nurses, Coordinator) Massimo Cacco Martina Mattiazzi (Client Relation Office - URP) Paolo Turri (Medical Services) Alberto Bortolami Mauro Pegoraro Gianni Forzan Fortunata Marchese (Education) Stefania Facchin Luciana Nalin Roberta Candian Marta Amato Michelle Elisabeth Quinn Nicoletta Zanotto Gloria Miarti Morena Piovan Donatella Pivetta Marica Pizzello Daniele Ciresola (Preventive Medicine) Cristina Maritan Michela Pinton Roberta Pozzani Lisa Rigato Silvia Volpi Marina Malipensa Sara Rossetti Federica Vascon Daniela Grosso ADMINISTRATIVE DIRECTORATE Pietro Girardi (Director) Marina Giusto (Deputy Director) Laura Scappin Giulia Di Chiara Simonetta Ive Cristina Ghirardello Roberta Signorini Paola Sorgato Emilio Pacchiega Isabella Calabrese Catia Farinea Franco Sterpi Margherita Casotto Manuela De Marchi Isabella Degli Agostini Lucia Lion Demis Sinigaglia Simone Polacco Filippo Paccanaro Michele Ferrin Federica Lea Margherita Merone Perone Emiliano Zabatta THE INSTITUTE - CHIEF OFFICER ADDRESS 18

19 CLINICAL ACTIVITY ORGANIZATION CLINICAL ACTIVITY ORGANIZATION 19

20

21 Chief Medical Officer Report CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 21

22 Chief Medical Officer Report Graduated in Medicine in 1976, Maria Giacobbo was from the beginning involved in public health management. Since 1986 she acted as Medical Director in several Hospitals and headed different Health Agencies of the Veneto Region; from 1993 to 2000 she was also engaged as teacher at the Post-Graduate School of Hygiene and Preventive Medicine of the University of Verona. Since 2008 she acts as Medical Director of the IOV. The Medical Directorate is responsible for the management of all the clinical activities, and for the global governance and integration of the services provided by the individual Units of the Institute. In this setting, the Medical Directorate plays a key role in mediating among the requirements of the Clinics (efficacy of interventions and maintenance of high standards of care), of the Research activities (need of innovation and experimentation), and of the Administrative area (efficient resource employment). This function guarantees to both IOV workers and the public (patients and Institutions) elevated and consistent levels of care, also dedicating special attention to crucial aspects of modern Oncology and Medicine: safeness and risk prevention; treatment appropriateness; equal opportunity of access to care; care humanization and strict observation of deontological rules. In this frame, the Medical Directorate is strongly motivated to develop and optimize, in steady collaboration with the other Directorates, new models of organization and governance which could improve the quality of the services in terms of efficacy, efficiency, safety, and appropriateness. The Medical Directorate includes several Offices, which superintend specific aspects of the clinical governance of the Institute: Quality and accreditation Chief: Daniela Chiusole This Office is dedicated to the following activities: to guarantee, monitor and verify the maintenance and implementation of the quality of services, by providing appropriate indexes of control; to promote among the personnel of the Institute the culture and value of the quality, through dedicated tools such as educational courses on quality assurance and control; to plan and monitor all the activities needed to obtain and maintain the institutional accreditation, according to national and regional rules and requirements; to organize, monitor and maintain the ISO 9001 certification, now extended to all the clinical and administrative activities of the Institute; CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 22

23 to interact with other IRCCS to promote shared standards of the quality assurance system among Institutions with similar features and mission, and to favor the constant amelioration of governance tools also in view of international models of quality governance. Working risk prevention and radioprotection Chief: Daniele Ciresola This Office superintends to monitor the health of all the workers of the Institute, with particular attention to the evaluation, prevention and follow-up of the professional risks of individual categories and typologies of employment. This endeavor is carried out according to the regulations provided by both national and regional risk prevention agencies. Client satisfaction and claims Chief: Martina Mattiazzi This Office monitors the perception of the quality offered by the clients or patients, and his mission is to exploit all the claims and/or suggestions by the public to implement the quality of the medical assistance, in strict collaboration with the Quality and Accreditation office. To this end, a 24h phone line is active to facilitate the interactions with patients and their caregivers; more than 2,000 contacts are established yearly. Furthermore, in collaboration with volunteers operating within the Institute, a continuous analysis of client satisfaction is performed by appropriate forms exploring the opinion of the patients on waiting times, perceived quality of services, including information on health status, and availability of medical and non-medical personnel. The relevant information is periodically collected and analyzed within the Medical Directorate. The Medical Directorate also superintends to other Units, in collaboration with other structures of the Institute; in particular, the Education Office and the Clinical Trial Office will be mentioned within the appropriate section. CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 23

24 Clinical Activity Data Hospitalisation Surgical index % 85% 80 67% 66% 60% % 34% 33% 20 15% 0 6% Inpatients Day Hospital Surgical Medical Inpatient admission by geographical areas Padua 57% 32% Veneto except Padua Northen Italy except Veneto Central Italy Southern Italy and Islands Outside Italy 1% 4% 3% 3% CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 24

25 DRG average relative weight Average length of stay 4,5 4,0 Medical I n p a t i e n t s 8 7 3,5 Surgical 6 3,0 2,5 2,0 1,5 1, Medical Inpatients 0,5 1 Surgical 0, Pathological examinations Endoscopic procedures Cytological Istological CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 25

26 Chemotherapy courses Radiodiagnostic and Nuclear Medicine examinations Inpatients Outpatients Nuclear medicine Radiodiagnostic Laboratory tests Outpatient visits CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 26

27 Radiation treatments Cardiologic examinations Inpatients Day Hospital CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 27

28 Multidisciplinary Groups The clinical and research activity of the Institute is carried out according to a model of multidisciplinarity. While this modality of approach to cancer patients fully fits the most accredited trends of modern Oncology, it also reflects the spirit of our Institute, where the presence of spikes of true excellence in some areas does not obscure the collegial work that permits the expression of this excellence. In other words, we are all convinced that the constant advancement of the clinical and research levels of our Institute, and the eventual steady improvement of the standards of care and the quality of life of our patients, only rely on the work of all of us. As in the functioning of a watch, the merit of indicating the real time is not attributable to one or the other piece composing the mechanism, but it is the result of the coordinated movement and function of all the parts of the watch. This spirit is reflected on the fact that most activities are carried out through organ-oriented multidisciplinary groups, which include all the experts needed to face a single pathology, from prevention to therapy to rehabilitation and palliation in terminal patients. This is possible because the IOV is embedded in a fertile milieu of different expertise, spread among the University of Padova and the other health structures operating in this area. Thus, some multidisciplinary groups also include researchers not formally belonging to IOV, and conversely many specialists belonging to IOV are asked to participate in clinical and research multidisciplinary groups based on other sanitary structures. This cross-fertilization makes it possible the constant rise to excellence of the Medicine and Oncology in Padova. The oncologic multidisciplinary groups operating since many years are listed in the Table with the indication of the contributing structures. CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 28

29 The experts of these groups meet at least at weekly intervals in fixed days, or if necessary in extemporary sessions. In these meetings, the clinical situation of every patient is collegially examined, and the most appropriate diagnostic/therapeutic plan is chosen. The patients are then also collegially re-evaluated during the treatment, and eventual decisions on the therapeutic layout stem from the discussion of the relevant experts. These meetings, beyond their importance for the management of the clinical situation of the patients, are also fundamental opportunities to generate new and foster existing scientific collaborations. Field of interest Units Brain tumors Clinical Oncology 1, Radiotherapy and Nuclear Medicine, Immunology and Molecular Oncology - IOV Pathology, Neurosurgery, Neuroradiology - University Hospital of Padua Breast tumors Breast surgery, Clinical Oncology 1 & 2, Radiotherapy and Nuclear Medicine, Breast Imaging, Radiology, Pathology, Immunology and Molecular Oncology, Hereditary Endrocrine Cancer Unit - IOV Clinical Surgery II - University Hospital of Padua Esophageal tumors Clinical Oncology 2, Radiotherapy and Nuclear Medicine, Immunology and Molecular Oncology, Radiology, Surgical Oncology - IOV Clinical Surgery I - University Hospital of Padua Lymphomas Clinical Oncology 2, Immunology and Molecular Oncology, Radiotherapy and Nuclear Medicine - IOV Hematology Unit, Pediatric Hematology-Oncology Unit of Department of Pediatrics - University Hospital of Padua Gynecologic cancers Clinical Oncology 1, Radiotherapy and Nuclear Medicine, Radiology - IOV Pathology, Clinical Surgery II, Gynecology - University Hospital of Padua Lung tumors Clinical Oncology 2, Radiotherapy and Nuclear Medicine, Radiology, Immunology and Molecular Oncology - IOV Thoracic Surgery - University Hospital of Padua Head/neck tumors Clinical Oncology 2, Radiotherapy and Nuclear Medicine, Pathology - IOV Otolaryngology Unit - University Hospital of Padua Thyroid tumors Clinical Oncology 1 & 2, Radiotherapy and Nuclear Medicine, Hereditary Endocrine Cancer Unit - IOV Surgical Pathology Unit, Endocrinology Unit - University Hospital of Padua Gastro-Intestinal tumors Clinical Oncology 1, Radiotherapy and Nuclear Medicine, Pathology, Radiology, Immunology and Molecular Oncology, Family Cancer Clinics - IOV Clinical Surgery II - University Hospital of Padua Surgery Branch - S. Antonio Hospital of Padua Melanoma Clinical Oncology 2, Melanoma and Soft Tissue Tumors Unit, Immunology and Molecular Oncology, Pathology, Radiotherapy and Nuclear Medicine - IOV Clinical Surgery II, Dermatology - University Hospital of Padua Soft Tissue Sarcomas Melanoma and Soft Tissue Tumors Unit, Clinical Oncology 1, Radiotherapy and Nuclear Medicine, Radiology - IOV Orthopedics, Radiology - University Hospital of Padua For Ewing sarcoma and rhabdomyosarcoma: periodical consultation with Pediatric Hematology-Oncology Unit - University Hospital of Padua Hepatic carcinoma and liver disease Clinical Oncology 1, Radiology - IOV Hepatobiliary surgery, Pathology - University Hospital of Padua CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 29

30 Peritoneal Carcinomatosis Tumors of the Urinary System and Male genital organs Melanoma and Soft Tissue Tumors Unit, Clinical Oncology1, Radiotherapy and Nuclear Medicine, Radiology - IOV Clinical Surgery II - University Hospital of Padua Medical Oncology I, Radiotherapy and Nuclear Medicine, Radiology - IOV Urology, Pathology, Cryopreservation of Male Gametes - Department of Medical and Surgical Sciences - University Hospital of Padua Pancreatic tumors Clinical Oncology 1, Radiology - IOV Clinical Surgery I & II - University Hospital of Padua Pediatric Soft tissue sarcomas and Pediatric brain tumors Radiotherapy and Nuclear Medicine, Clinical Oncology 1, Anesthesiology - IOV Pediatric Hematology-Oncology Unit - University Hospital of Padua Family Cancer Clinics The interest in heredo-familial tumors originated in the late 90s, much before the birth of IOV, thanks to the illuminated idea of a group of researchers of the Department of Oncology and Surgical Sciences of the University of Padua (Emma D Andrea, Marco Montagna, Chiara Menin), who subsequently joined the IOV. At the beginning, the interest was centered on breast and ovary tumors, where inheritable alterations of the BRCA1-2 genes had been first documented. Later on, the attention was extended to heredo-familial melanoma, and a further drive was given when an academic endocrinologist (Giuseppe Opocher) with a strong interest and expertise in inheritable neuroendocrine tumors joined the IOV. At that time (2009) an operative Unit was founded, denominated Family Cancer Clinics. This Unit, coordinated by Professor Opocher, collects the entire expertise on the field of heredo-familial tumors expressed within the Institute (and partly outside, as we shall see later). The Family Cancer Clinics structure has the responsibility for managing the afflux of patients to the structures where specific genetic testing and counseling is performed, organizing blood sampling for genetic tests, distributing these samples to the concerned laboratories, and collecting results for further contacts with the patients. Even though the interest in heredo-familial cancers is widespread among Italian IRCCS, the IOV Family Cancer Clinics is the sole structure collecting in a single operating unit the management of these conditions, thus contributing to increase the critical mass in the field. In addition, the Family Cancer Clinics works in strict contact and collaboration with a research group dedicated to the study of heredo-familial colorectal cancer. This surgical group, wich operates at the University of Padova-Padova General Hospital under the direction of Professor Donato Nitti, over the last 10 years has focused his interest on these neoplasms; its activity entails counseling, genetic testing, and most importantly a certified tissue bank which has collected over the years more than 20,000 biological samples from about 2,000 patients. It is a firm auspice and hope of the Scientific Direction of the IOV that these structures could soon converge into a single inter-institutional Unit, where the critical mass, the mechanistic knowledge, and the quality of assistance could undergo a terrific growth. CLINICAL ACTIVITY ORGANIZATION - CHIEF MEDICAL OFFICER REPORT 30

31 THE DEPARTMENTS THE DEPARTMENTS 31

32 THE DEPARTMENTS CLINICAL ONCOLOGY SURGERY IMAGING, RADIOLOGY & PATHOLOGY RADIOTHERAPY & NUCLEAR MEDICINE EXPERIMENTAL, LABORATORY & TRANSLATIONAL ONCOLOGY SERVICES THE DEPARTMENTS 32

33 Department of Clinical Oncology THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 33

34 Clinical Oncology 1 Chief Vittorina Zagonel, MD Vittorina Zagonel worked at the Clinical Oncology Division of the CRO Aviano Cancer Center (IRCCS) from 1983 to From 2000 to 2009, she served as Head of the Clinical Oncology Unit at the Fatebenefratelli Hospital, Rome, where she also acted as Director of the Department of Oncology for eight years. Since October 2009 she has been serving as Head of the Clinical Oncology 1 at Istituto Oncologico Veneto (Padua). She was a member of the National Oncologic Committee and a member of the Ministry of Health board for palliative care in She coordinates the AIOM task force on Continuous Care in Oncology since She is author and coauthor of more than 150 articles in indexed journals. Main Pubblications Detecting functional impairment in older patients with cancer: is vulnerable elders survey-13 the right prescreening tool? An open question. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. Advanced gastric cancer (GC) and cancer of the gastrooesophageal junction (GEJ): focus on targeted therapies. Falci C, Brunello A, Monfardini S. J Clin Oncol. 2010; 28:665-6 Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G, Zagonel V. Cancer. 2011; 117: J Clin Oncol. 2011; 29: Crit Rev Oncol Hematol. 2011; in press. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, Brunello A, Cappetta A, Zagonel V. Oncologist. 2011; 16: THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 34

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Breast. Patient information. cancer clinical pathway

Breast. Patient information. cancer clinical pathway Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology INTRODUCTION 2009 A university wishing to have an accredited program in Pediatric Hematology/Oncology must also

More information

Master Online Study Program @dvanced Oncology. Study part time team up internationally!

Master Online Study Program @dvanced Oncology. Study part time team up internationally! Master Online Study Program @dvanced Oncology Study part time team up internationally! Ulm University is developing an innovative international postgraduate study program @dvanced Oncology addressing clinical

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery Cancer treatment TOP EUROPEAN CANCER EXPERTISE The path to recovery 0% LAND OF HIGH QUALITY HEALTHCARE Located in Finland, a land of high quality healthcare, Helsinki University Hospital is regarded as

More information

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Mediterranean School of Oncology

Mediterranean School of Oncology Mediterranean School of Oncology Organized and supported by: CINBO Consorzio Interuniversitario Nazionale per la Bioncologia HIGHLIGHTS IN THE MANAGEMENT OF COLORECTAL CANCER, February 1-2, 2007 Domus

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

Specific Standards of Accreditation for Residency Programs in General Surgery

Specific Standards of Accreditation for Residency Programs in General Surgery Specific Standards of Accreditation for Residency Programs in General Surgery 2010 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation of the

More information

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.

The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Irene Catucci 1,2,12, Paolo Verderio 3,12, Sara Pizzamiglio 3,12, Siranoush Manoukian 4, Bernard Peissel 4, Daniela Zaffaroni

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information

C a nc e r C e nter. Annual Registry Report

C a nc e r C e nter. Annual Registry Report C a nc e r C e nter Annual Registry Report 214 214 Cancer Registry Report Larraine A. Tooker, CTR Please note that the 214 Cancer Registry Annual Report is created in 214, but it reflects data on cases

More information

E UROPEAN CURRICULUM VITAE FORMAT

E UROPEAN CURRICULUM VITAE FORMAT E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

The Brain and Spine CenTer

The Brain and Spine CenTer The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Biomarker Trends in Breast Cancer Research

Biomarker Trends in Breast Cancer Research WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

Journey in the Academic and Research world of Italy Anna Maria Fioretti

Journey in the Academic and Research world of Italy Anna Maria Fioretti Journey in the Academic and Research world of Italy Anna Maria Fioretti The Regina Elena National Cancer Institute (I.R.E.) part of the Italian network of the LR. C CS. (Istituti di Ricovero e Cura a Carattere

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used? Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Hosts. New Methods for Treating Colorectal Cancer

Hosts. New Methods for Treating Colorectal Cancer Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

New Treatment Advances for Breast Cancer

New Treatment Advances for Breast Cancer New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center

More information

KINGS COUNTY HOSPITAL CENTER EXECUTIVE SUMMARY. Always Here When You Need Us

KINGS COUNTY HOSPITAL CENTER EXECUTIVE SUMMARY. Always Here When You Need Us KINGS COUNTY HOSPITAL CENTER EXECUTIVE SUMMARY Always Here When You Need Us Kings County Hospital Center Cancer Care Program ANNUAL REPORT 2013: EXECUTIVE SUMMARY The Kings County Hospital Center Cancer

More information

NCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital

NCI Community Cancer Centers Program Program Overview Ascension Health St. Vincent Indianapolis Hospital A. Name and location of hospital:, Indianapolis, IN B. Name of cancer center: St. Vincent Oncology Center C. Identify PI and key personnel with contact information for each pilot focus areas: a. Disparities

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

CURRICULUM VITAE Mariano Ferraresso, M.D., Ph.D.

CURRICULUM VITAE Mariano Ferraresso, M.D., Ph.D. CURRICULUM VITAE Mariano Ferraresso, M.D., Ph.D. Birthday and Place : Permanent Address : Nationality : Present Position : August 21 st, 1961. Piove di Sacco (Padova), Italy Via E. Caruso, 2-20133 Milano

More information

Guidelines for Management of Renal Cancer

Guidelines for Management of Renal Cancer Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated

More information

Cancer Services for Adults and Children

Cancer Services for Adults and Children UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer

More information

Rilevanza dell innovazione tecnologica per la

Rilevanza dell innovazione tecnologica per la Rilevanza dell innovazione tecnologica per la ricerca traslazionale e la terapia in oncologia Ruggero De Maria Dipartimento di Ematologia Oncologia e Medicina Molecolare, Istituto Superiore di Sanità Translational

More information

TRAINING IN SURGERY IN GREECE

TRAINING IN SURGERY IN GREECE TRAINING IN SURGERY IN GREECE George N Zografos Consultant Surgeon, Athens General Hospital General Secretary Hellenic Surgical Association National Delegate, UEMS Division of General Surgery STATISTICAL

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

16.30 Kaposi s Sarcoma (KS): an interesting model for studying clinico-pathological relationship in tumorigenesis events

16.30 Kaposi s Sarcoma (KS): an interesting model for studying clinico-pathological relationship in tumorigenesis events VIII th M.O.M.T. MEDITERRANEAN CONGRESS ON ONCOLOGICAL PATHOLOGY GALLIPOLI (LE) October 2015, 9-10 Convention Center - Grand Hotel Costa Brada Gallipoli (LE), ITALY 1 st day, Friday, October 2015, 9 8.30

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3 1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point

More information

Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it

Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it The University of Udine is an Italian Public University founded in 1978 by National Law No. August 8, 1977 546, art.

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD

Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION

More information

Treatment Advances for Liver Cancer

Treatment Advances for Liver Cancer Treatment Advances for Liver Cancer Guest Expert: Wasif, MD Associate Professor of Medical Oncology Mario Strazzabosco, MD Professor of Internal Medicine, Digestive Diseases www.wnpr.org www.yalecancercenter.org

More information

High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem

High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem rmerrell@northshore.org Objectives Provide updates on

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

Ministero della Salute

Ministero della Salute Ministero della Salute Direzione Generale della Ricerca e dell' Innovazione in Sanità BANDO 2013 PROGRAMMI DI RETE FINANZIATI PROGRAMMA NETWORK CODICE: 02356160 SCORE MEDIO DEL NETWORK: 13,75 Pediatric

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Houston Cancer Institute

Houston Cancer Institute Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Advanced Prostate Cancer Treatments

Advanced Prostate Cancer Treatments Advanced Prostate Cancer Treatments Guest Expert: Kevin, DO Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

What is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM?

What is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM? GBM (English) What is Glioblastoma? Glioblastoma or glioblastoma multiforme is one of the most common brain tumors accounting for approximately 12 to 15 percent of all brain tumors. The name of the tumor

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Oncology Nurse Care Coordinators as. Navigators. Improving cancer disease management and the patient experience

Oncology Nurse Care Coordinators as. Navigators. Improving cancer disease management and the patient experience Oncology Nurse Care Coordinators as Navigators Improving cancer disease management and the patient experience Oncology nurses have always played a crucial role in coordinating physicians, other cancer

More information

Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta

Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Locoregional & advanced esophagus or esophagogastric junction cancer

Locoregional & advanced esophagus or esophagogastric junction cancer Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription

More information

FACULTY OF ALLIED HEALTH SCIENCES

FACULTY OF ALLIED HEALTH SCIENCES FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information